) recently announced phase II data on its oncology candidate,
bavituximab. The open-label, randomized phase II study was
conducted in patients suffering from previously untreated,
advanced Stage IV pancreatic cancer.
The study compared bavituximab plus
) Gemzar (gemcitabine) to Gemzar alone. Results showed that
patients in the combination arm had a 28% tumor response rate
compared to 13% in the Gemzar arm. However, median overall
survival, which was the primary endpoint, was modest at 5.6
months for the combination arm versus 5.2 months for the Gemzar
Bavituximab in combination with Gemzar was found to be safe
and well tolerated with similar adverse events occurring in both
Peregrine Pharma intends to analyze the results further and
present the same at a scientific meeting later this year.
Bavituximab is a key pipeline candidate at Peregrine Pharma.
Bavituximab is being studied for several indications including
non-small cell lung cancer in the front and second-line settings,
breast, prostate, liver and rectal cancers in combination with
approved chemotherapies and radiation.
We note that last year, the company had presented results on
bavituximab from a phase II study for second-line non-small cell
lung cancer. However, later on, Peregrine Pharma had said that
the data could not be relied on due to certain discrepancies
between some patient sample test results and patient treatment
Earlier this year, Peregrine Pharma provided an update on the
situation and provided information from an internal review of the
The company said that discrepancies were isolated to the
placebo and 1 mg/kg treatment arms of the trial with no evidence
of discrepancies in the 3 mg/kg treatment arm of the trial.
Peregrine Pharma intends to announce detailed results from the
Peregrine Pharma currently carries a Zacks Rank #3 (Hold). We
expect investor focus to remain on updates on the future
development path for bavituximab. Biopharma companies that
currently look more attractive include
). Both are Zacks Rank #1 stocks (Strong Buy).
CYTOKINETCS INC (CYTK): Free Stock Analysis
LILLY ELI & CO (LLY): Free Stock Analysis
PEREGRINE PHARM (PPHM): Free Stock Analysis
TARGACEPT INC (TRGT): Free Stock Analysis
To read this article on Zacks.com click here.